CA2471833A1 - Procedes et compositions pour normaliser les niveaux lipidiques dans les tissus mammaliens - Google Patents

Procedes et compositions pour normaliser les niveaux lipidiques dans les tissus mammaliens Download PDF

Info

Publication number
CA2471833A1
CA2471833A1 CA002471833A CA2471833A CA2471833A1 CA 2471833 A1 CA2471833 A1 CA 2471833A1 CA 002471833 A CA002471833 A CA 002471833A CA 2471833 A CA2471833 A CA 2471833A CA 2471833 A1 CA2471833 A1 CA 2471833A1
Authority
CA
Canada
Prior art keywords
cgrp
receptor
agonist
amylin
high affinity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002471833A
Other languages
English (en)
Inventor
Garth James Smith Cooper
Kerry Martin Loomes
Rachel Nancy Watson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protemix Corp Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2471833A1 publication Critical patent/CA2471833A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)

Abstract

L'invention concerne des procédés permettant de stimuler la lipolyse dans des cellules et tissus mammaliens par contact de la cellule ou du tissu avec un agoniste d'un récepteur de CGRP, par exemple le récepteur de CGRP à affinité élevée. L'agoniste peut, de préférence, stimuler le récepteur CGRP à affinité élevée en comparaison avec le récepteur d'amyline métabolique. L'invention concerne également des procédés de criblage permettant d'identifier des agonistes de récepteur, des compositions renfermant de tels agonistes et des schémas thérapeutiques faisant appel à de tels agonistes.
CA002471833A 2001-11-26 2002-11-26 Procedes et compositions pour normaliser les niveaux lipidiques dans les tissus mammaliens Abandoned CA2471833A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33342201P 2001-11-26 2001-11-26
NZ515731 2001-11-26
US60/333,422 2001-11-26
NZ51573101 2001-11-26
PCT/NZ2002/000262 WO2003045424A1 (fr) 2001-11-26 2002-11-26 Procedes et compositions pour normaliser les niveaux lipidiques dans les tissus mammaliens

Publications (1)

Publication Number Publication Date
CA2471833A1 true CA2471833A1 (fr) 2003-06-05

Family

ID=26652295

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002471833A Abandoned CA2471833A1 (fr) 2001-11-26 2002-11-26 Procedes et compositions pour normaliser les niveaux lipidiques dans les tissus mammaliens

Country Status (6)

Country Link
EP (1) EP1461068A4 (fr)
JP (1) JP2005523418A (fr)
CN (1) CN1617737A (fr)
AU (2) AU2002356469A1 (fr)
CA (1) CA2471833A1 (fr)
WO (1) WO2003045424A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1324234A (zh) 1998-09-25 2001-11-28 格利科克斯有限公司 果糖胺氧化酶,拮抗剂和抑制剂
WO2003077901A1 (fr) 2002-03-08 2003-09-25 Protemix Corporation Limited Prevention et/ou traitement de maladie cardio-vasculaire et/ou d'insuffisance cardiaque connexe
JP2006503014A (ja) 2002-08-20 2006-01-26 プロテミックス コーポレイション リミティド 剤形及び関連する治療法
ES2449066T3 (es) 2004-07-19 2014-03-18 Philera New Zealand Limited Síntesis de trietilentetraminas
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
US9855332B2 (en) 2011-05-20 2018-01-02 Alderbio Holdings Llc Use of anti-CGRP antibodies and antibody fragments to treat diarrhea in subjects with diseases or treatments that result in elevated CGRP levels
TWI646111B (zh) 2011-05-20 2019-01-01 艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽（ａｎｔｉ－ｃｇｒｐ）組成物及其用途
AU2012258980B8 (en) 2011-05-20 2017-06-15 H. Lundbeck A/S Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
JP6502337B2 (ja) * 2013-07-03 2019-04-17 アルダー・バイオファーマシューティカルズ・インコーポレーテッド 抗ｃｇｒｐ抗体を使用したグルコース代謝の調整
JP2022516956A (ja) 2019-01-08 2022-03-03 ハー・ルンドベック・アクチエゼルスカベット 抗ｃｇｒｐ抗体を用いた頭痛の急性治療及び迅速治療

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
US5175145A (en) * 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
AU6524794A (en) * 1993-03-24 1994-10-11 Amylin Pharmaceuticals, Inc. Cloned receptors and methods for screening
JPH10504457A (ja) 1994-08-16 1998-05-06 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド カルシトニンレセプター
AU6596096A (en) * 1996-07-23 1998-02-10 Smithkline Beecham Corporation Calcitonin gene-related peptide receptor component factor (houdc44)
CN1055640C (zh) 1996-11-29 2000-08-23 沃维汉 人降钙素基因相关肽脂质体组合物及其制法
ES2356595T3 (es) * 1998-02-13 2011-04-11 Amylin Pharmaceuticals, Inc. Nuevos compuestos de actividad mixta de la amilina.

Also Published As

Publication number Publication date
AU2002356469A1 (en) 2003-06-10
CN1617737A (zh) 2005-05-18
EP1461068A4 (fr) 2006-03-29
EP1461068A1 (fr) 2004-09-29
WO2003045424A1 (fr) 2003-06-05
AU2009201147A1 (en) 2009-04-23
AU2002356469A2 (en) 2003-06-10
JP2005523418A (ja) 2005-08-04

Similar Documents

Publication Publication Date Title
AU2009201147A1 (en) Methods and Compositions for Normalizing Lipid Levels in Mammalian Tissues
US7803557B2 (en) Methods for identification of eicosapentaenoic acid analogs using anti-inflammatory receptors
Perello et al. Differential effects of fasting and leptin on proopiomelanocortin peptides in the arcuate nucleus and in the nucleus of the solitary tract
McKie et al. Biochemical adaptations in white adipose tissue following aerobic exercise: from mitochondrial biogenesis to browning
EP1817583A2 (fr) Gènes et polypeptides associés au transport du glucose et procédés d'utilisation de ceux-ci
Tollet-Egnell et al. Growth hormone-mediated alteration of fuel metabolism in the aged rat as determined from transcript profiles
US20040038861A1 (en) Methods and compositions for normalizing lipid levels in mammalian tissues
WO2005005665A1 (fr) Methode d'evaluation de compose efficace dans le traitement de l'obesite
WO2000075166A1 (fr) Recepteur de l'hormone concentratrice de la melanine
JP2004533225A (ja) インスリン及びそのアンタゴニストのためのリンタンパク質標的
WO2005095972A2 (fr) Composes destines au diagnostic et au traitement de maladies associees au recepteur couple aux proteines g etb (etb)
US8252525B2 (en) Diagnostics and therapeutics for diseases associated with G-protein coupled receptor AdipoR1(AdipoR1)
NZ542281A (en) Methods and compositions for normalizing muscle lipid levels using CGRP-1
Oana et al. DNA microarray analysis of white adipose tissue from obese (fa/fa) Zucker rats treated with a β3-adrenoceptor agonist, KTO-7924
WO2004082568A2 (fr) Diagnostics et traitements contre des maladies associees au recepteur 5a du composant du complement (c5ar)
Polak et al. Acute exposure to long-chain fatty acids impairs α2-adrenergic receptor-mediated antilipolysis in human adipose tissue
JP2007506950A (ja) Ｇタンパク質共役受容体ＡｄｉｐｏＲ２（ＡｄｉｐｏＲ２）に関連する疾患の診断および治療
EP1606633B1 (fr) Diagnostics et traitements contre des maladies associees au recepteur d3 de la dopamine (drd3)
Saito et al. G‐Protein–Coupled Receptor Deorphanizations
Harant et al. Atrial natriuretic peptide contribution to lipid
Nugent OB-AGE, an EU project to tackle the metabolic syndrome: project update.
JP2006290885A (ja) インスリン抵抗性およびインスリン抵抗性を特徴とする疾病状態の治療方法
WO2007019410A2 (fr) Recepteurs d'obestatine de mammiferes
US20060263359A1 (en) Diagnostics and therapeutics for diseases associated with dopamine receptor d4 (drd4)
Wilson et al. Glycogenin protein and mRNA expression in response to

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead